SCHEMBL19006327

SCHEMBL19006327

NC(N)c1ccc(/N=N/Nc2ccccc2C#Cc2ccccc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
MAPT P10636 4/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
HPGD P15428 2/20 0.38
CYP2C19 P33261 2/20 0.38
HSD17B10 Q99714 2/20 0.38
MAPK1 P28482 2/20 0.38
CYP2D6 P10635 1/20 0.38
KDM4E B2RXH2 3/20 0.37
NPC1 O15118 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 2/20 0.36
CYP1B1 Q16678 2/20 0.35
CYP1A1 P04798 1/20 0.35
TSHR P16473 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17469669 0.80 TMPRSS2 (0.52) ALDH1A1MEN1KMT2AMAPTCYP1A2
SCHEMBL21152016 0.68 ACACB (0.35) MEN1KMT2ANPC1RAB9AAPP
SCHEMBL21153028 0.68 NPC1 (0.40) ALDH1A1MEN1KMT2AMAPTHPGD
SCHEMBL17469632 0.67 SLC16A3 (0.40) ALDH1A1MEN1KMT2AMAPTCYP1A2
SCHEMBL14494496 0.63 ALDH1A1 (0.53) ALDH1A1MEN1KMT2AMAPTCYP1A2
SCHEMBL17469661 0.61 TMPRSS2 (0.56) ALDH1A1MEN1KMT2AMAPTCYP1A2
SCHEMBL16213446 0.61 KDM4E (0.65) ALDH1A1MEN1KMT2AMAPTCYP1A2
SCHEMBL2114742 0.61 APP (0.75) ALDH1A1MEN1KMT2AMAPTCYP1A2
SCHEMBL5871989 0.61 APP (0.75) ALDH1A1MEN1KMT2AMAPTCYP1A2
SCHEMBL17469666 0.60 TMPRSS2 (0.61) ALDH1A1MEN1KMT2AMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170174620-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME UNIVERSITY OF MARYLAND, COLLEGE PARK 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174620-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME MCL1, DPYD, TOP2B ALDH1A1 635/4885MEN1 1462/4885KMT2A 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.